AstraZeneca Wins U.S. Approval for Baxfendy, Eyeing Over $5 Billion in Peak Sales
Updated
Updated · Reuters · May 18
AstraZeneca Wins U.S. Approval for Baxfendy, Eyeing Over $5 Billion in Peak Sales
12 articles · Updated · Reuters · May 18
Baxfendy won U.S. approval for adults with uncontrolled high blood pressure, giving AstraZeneca a new treatment option to use alongside existing antihypertensive drugs.
Late-stage trial data underpinned the decision: the 2 mg dose cut systolic blood pressure by 9.8 mmHg at 12 weeks versus placebo-adjusted baseline, while the 1 mg dose lowered it by 8.7 mmHg.
The pill works by blocking aldosterone production, targeting hormonal drivers of hypertension that older treatments such as diuretics and ACE inhibitors do not directly address.
AstraZeneca said the drug could exceed $5 billion in peak annual sales, and the approval puts it ahead of Mineralys Therapeutics, whose rival lorundrostat faces a U.S. decision in December.
The clearance opens a large market: about 120 million U.S. adults have high blood pressure, and AstraZeneca is also testing Baxfendy in chronic kidney disease and heart failure.
With a rival drug nearing approval, can Baxfendy truly dominate the market for uncontrolled hypertension?
Will this new drug's hormone-blocking action finally prevent heart and kidney damage from high blood pressure?
Baxfendy (Baxdrostat) FDA Approval: First-in-Class Aldosterone Synthase Inhibitor Redefines Hypertension Treatment in 2026
Overview
On May 18, 2026, the FDA approved Baxfendy (baxdrostat), making it the first aldosterone synthase inhibitor (ASI) for treating hypertension. Baxfendy works by specifically inhibiting the production of aldosterone, a hormone that raises blood pressure and increases the risk of heart and kidney problems. This new medication offers a novel option for adults whose blood pressure remains high despite other treatments. By targeting aldosterone, Baxfendy introduces a fresh approach to blood pressure management, addressing a significant unmet need for patients with uncontrolled hypertension and marking a major advancement in cardiovascular care.